{
  "id": 5094079,
  "title": "STAT+: Pharmalittle: We’re reading about a Huntington’s gene therapy, Novo’s challenges, and more",
  "url": "https://urgent.news/2026/09/02/stat-pharmalittle-were-reading-about-a-huntingtons-gene-therapy-novos",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-02T13:26:55.000Z",
  "source": {
    "name": "STAT News",
    "slug": "stat-news",
    "url": "https://www.statnews.com/pharmalot/2026/09/02/uniqure-huntingtons-fda-novo-nordisk-investors-pharmalittle-newsletter/"
  },
  "original_language": "en",
  "account": "Hello from STAT's London office, where Andrew Joseph takes the helm for Pharmalot. It's a Wednesday, and we're diving into today's headlines. The White House's recent drug pricing agreements with companies may not have an immediate impact, as they mainly cover Medicaid, which already receives the lowest prices. The deals also exempt companies from mandatory Medicare price reductions. UniQure submitted its experimental Huntington's gene therapy to the FDA for an accelerated approval review, despite initial rejections based on a Phase 1/2 trial. The FDA later reversed its decision in June, and UniQure has also applied for approval in the U.K. For more details, check out STAT+.",
  "summary": "UniQure has submitted its Huntington’s gene therapy to the FDA, investors remain unenthusiastic on Novo Nordisk, and more of the latest pharma headlines in today's Pharmalittle newsletter.",
  "key_points": [
    "White House drug pricing deals with limited immediate impact",
    "UniQure's Huntington's gene therapy submitted to FDA for accelerated approval",
    "FDA reversed initial rejection in June, UniQure applied for U.K. approval"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "BioPharma Dive",
        "title": "UniQure, after setbacks, seeks FDA approval of Huntington’s gene therapy",
        "url": "https://urgent.news/2026/09/02/uniqure-after-setbacks-seeks-fda-approval-of-huntingtons-gene-therapy",
        "published": "2026-09-02T15:22:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}